![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Abacus Diagnostica Gets CE Mark for Its GenomEra COVID-19 Test
Abacus Diagnostica Gets CE Mark for Its GenomEra COVID-19 Test
Abacus Diagnostica, part of the Finnish company Uniogen, has received a CE mark for its second-generation COVID-19 test, the GenomEra SARS-CoV-2 2.0 assay kit.
The polymerase chain-reaction (PCR) test, which has 98.3 percent sensitivity and 99.8 percent specificity, is intended for use by healthcare professionals and can detect the SARS-CoV-2 virus in respiratory samples in 50 minutes.
The test’s performance is not affected by the emergence of new COVID-19 variants as it simultaneously detects two different targets in the SARS-CoV-2 virus genome, the company said.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct